Latest

• New drug submissions in the United States and Canada 2014-2019: trends and policy implications.

  Canada may have passed a tipping point where we are no longer considered a premier jurisdiction to launch new medicines. »

• Potential impact of U.S. demand on the Canadian supply of 46 prescription drugs.

  U.S. importation impact on the Canadian drug supply will affect specific patient populations differently; the Canadian drug supply cannot sustain increased demand from Americans. »

• New pathways for U.S. importation threaten Canadian prescription drug supply.

  Serious drug shortages are predicted unless Canada puts a halt to exporting drugs to the U.S. »

• Preventive care of the future? Economic analysis of cardiovascular risk management.

  Some innovative medical clinics provide an alternative to the traditional curative care provided in the public health system, especially in hospitals. »

• The costs of Immunoglobulin treatment in hospital and in the home in Quebec

  Study examines the improvements in cost and quality of service arising from administration of Ig treatments in the home as opposed to in a hospital setting. »

• Coverage of new medicines in Federal-Provincial public drug plans in Canada 2009-2018

  Data reflect poorly on prospects for national pharmacare and the performance of the pan-Canadian Pharmaceutical Alliance (pCPA). »

• Coverage of new medicines in private versus public drug plans in Canada 2009-2018

  Public plans cover far fewer new drugs compared to private plans in Canada. Public plans also take much longer to cover new drugs compared to private plans. »

• Clinical Duty to Recontact in Genetic Testing: Insights from the Safety-Related Duty to Recall.

  When the understanding of relevant science no longer supports prior interpretation of a test result, is there a duty to recontact previously tested patients to inform them of the implications of these changes? »

• Patented drug prices and clinical trials in 31 OECD countries 2017: implications for Canada’s PMPRB.

  PMPRB regulatory changes will likely cause a substantial decline in the number of industry-funded clinical trials in Canada. »